Roundup

Five things for health marketers to know: Wednesday, December 1, 2021

Lecia Bushak

December 1, 2021

5:00 am

CDC recommends booster shots for all adults; FDA discusses authorization of Merck antiviral; Immunogen drug shrinks tumors in ovarian cancer patients.

Five things for health marketers to know: Tuesday, November 30, 2021

Lecia Bushak

November 30, 2021

5:00 am

Biden: FDA and CDC ready to move quickly on Omicron variant; Blueprint buys Lengo Therapeutics; Yvonne Greenstreet to become Alnylam CEO.

Five things for health marketers to know: Monday, November 29, 2021

Lecia Bushak

November 29, 2021

5:00 am

COVID-19 cases surge in Europe; FDA places clinical hold on Kura Oncology trial; Immunotherapy companies tackle food allergies.

Five things for health marketers to know: Wednesday, November 24, 2021

Lecia Bushak

November 24, 2021

5:00 am

Biden administration has no plans to reimpose COVID-19 lockdown; former FDA chief Hahn called to testify before Congress; federal jury finds CVS, Walgreens and Walmart responsible in opioid crisis.

Five things for health marketers to know: Tuesday, November 23, 2021

Lecia Bushak

November 23, 2021

5:00 am

90% of federal employees have received at least one dose of COVID-19 vaccine; Elizabeth Holmes testifies for first time in fraud trial; Sanofi partners with Baidu to pursue mRNA pipeline.

Five things for health marketers to know: Monday, November 22, 2021

Lecia Bushak

November 22, 2021

5:00 am

FDA authorizes Pfizer, Moderna boosters for all adults; Democrats’ pricing proposal clears hurdle; FDA places BioNTech skin cancer therapy on fast track.

Five things for health marketers to know: Friday, November 19, 2021

Lecia Bushak

November 19, 2021

5:00 am

U.S. buys 10 million courses of Pfizer COVID-19 pill; CVS Health to close 900 stores as part of move toward health services; Novo Nordisk acquires RNAi pioneer Dicerna for $3.3 billion.

Five things for health marketers to know: Thursday, November 18, 2021

Lecia Bushak

November 18, 2021

5:00 am

Moderna files FDA booster shot application; U.S. drug overdose deaths reach record high during pandemic; EU regulators give thumbs-down to Aduhelm.

Five things for health marketers to know: Wednesday, November 17, 2021

Lecia Bushak

November 17, 2021

5:00 am

Pfizer allows low-income countries to make and sell its COVID-19 pill cheaply; ViaCyte and CRISPR test type 1 diabetes cell therapy in new clinical trial; Moderna in talks to donate more vaccine doses to COVAX.

Five things for health marketers to know: Tuesday, November 16, 2021

Lecia Bushak

November 16, 2021

5:00 am

U.S. COVID-19 cases increase again after post-Delta drop; Bristol Myers Squibb/Janssen blood thinner shows success in trial; Medidata co-founder Glen de Vries dies in plane crash.

Five things for health marketers to know: Monday, November 15, 2021

Lecia Bushak

November 15, 2021

5:00 am

Biden nominates Califf to lead FDA; J&J splits pharma and consumer groups; Organon acquires Forendo Pharma.

Five things for health marketers to know: Friday, November 12, 2021

Lecia Bushak

November 12, 2021

5:00 am

Texas ban on mask mandates in schools deemed a violation of federal law; Cortexyme plans to push forward on Alzheimer’s drug after failed trial; FDA recalls Allume at-home COVID tests.

Five things for health marketers to know: Thursday, November 11, 2021

Lecia Bushak

November 11, 2021

5:00 am

900,000 kids receive first Pfizer shot; Moderna/NIH dispute over vaccine patent heads to court; Inventprise receives $90 million in funding from Gates Foundation.

Five things for health marketers to know: Wednesday, November 10, 2021

Lecia Bushak

November 10, 2021

5:02 am

Pfizer asks FDA to authorize booster shots for all adults; Oklahoma Supreme Court rejects J&J opioid epidemic ruling.

Five things for health marketers to know: Tuesday, November 9, 2021

Lecia Bushak

November 9, 2021

5:00 am

Biden administration to defend mandates against legal challenges; Regeneron antibodies reduce COVID risk by 82%; EU to provide recommendations for Merck’s antiviral COVID pill.